Background: Solriamfetol is approved (US and EU) for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea.
Objectives: Evaluate solriamfetol safety/efficacy for EDS in Parkinson's disease (PD).
Methods: Phase 2, double-blind, 4-week, crossover trial: adults with PD and EDS were randomized to sequence A (placebo, solriamfetol 75, 150, 300 mg/d), B (solriamfetol 75, 150, 300 mg/d, placebo), or C (placebo). Outcomes (safety/tolerability [primary]; Epworth Sleepiness Scale [ESS]; Maintenance of Wakefulness Test [MWT]) were assessed weekly. P values are nominal.
Results: Common adverse events (n = 66): nausea (10.7%), dizziness (7.1%), dry mouth (7.1%), headache (7.1%), anxiety (5.4%), constipation (5.4%), dyspepsia (5.4%). ESS decreased both placebo (-4.78) and solriamfetol (-4.82 to -5.72; P > 0.05). MWT improved dose-dependently with solriamfetol, increasing by 5.05 minutes with 300 mg relative to placebo (P = 0.0098).
Conclusions: Safety/tolerability was consistent with solriamfetol's known profile. There were no significant improvements on ESS; MWT results suggest possible benefit with solriamfetol in PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596433 | PMC |
| http://dx.doi.org/10.1002/mds.28702 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends and variation in issuance of high-cost narcolepsy drugs by NHS England organisations and regions from 2019 to 2022.
J Sleep Res
December 2024
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Clinicians and people with narcolepsy report varied access to higher-cost narcolepsy treatments in England associated with variations in national and local commissioning. There are no publicly available data quantifying use of these drugs to support policy decisions. We therefore aimed to describe national, regional and local prescribing trends for higher-cost narcolepsy drugs using new national databases.
View Article and Find Full Text PDFEvaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database.
Front Pharmacol
November 2024
Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Spain.
Article Synopsis
- The study investigates the safety of various medications for narcolepsy, a lifelong neurological disorder, using five years of data from the FDA Adverse Event Reporting System (FAERS) to analyze pharmacological treatments like pitolisant, sodium oxybate, solriamfetol, and modafinil.
- Data analysis revealed significant signals for adverse drug events (ADEs), especially psychiatric and nervous system-related issues, with sodium oxybate raising concerns about suicidal thoughts and respiratory problems, while other medications highlighted issues like drug inefficacy and pregnancy-related risks.
- Overall, findings suggest that adverse reactions align with existing product warnings, emphasizing the need for careful management and monitoring of narcolepsy treatments.
Results of the SHARP Study: A Randomized, Placebo-Controlled, Double-Blind, Repeated-Measures, Crossover, Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in OSA With Excessive Daytime Sleepiness and Cognitive Impairment.
Chest
November 2024
Axsome Therapeutics, New York, NY.
Article Synopsis
- OSA leads to disrupted sleep, excessive daytime sleepiness, and cognitive deficits.
- Solriamfetol was tested in a study involving 59 participants to determine its effects on cognitive function in OSA patients.
- Results showed significant improvements in cognitive scores and related assessments after taking solriamfetol, with minimal side effects like nausea and anxiety.
Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database.
Heliyon
October 2024
Neurological Care Unit, The First Affiliated Hospital of Fujian Medical University, NO.20 Chazhong Road, Fuzhou, 350001, Fujian, China.
Article Synopsis
- Solriamfetol is a medication used for excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea, but its long-term safety profile was previously unclear.
- A study analyzed real-world adverse events (AEs) associated with solriamfetol using the FDA’s Adverse Event Reporting System (FAERS) from 2019 to 2023, revealing 1659 reports where solriamfetol was the primary suspect.
- The research identified 74 significant adverse events across various organ systems, including 16 unexpected AEs not listed in the FDA label, indicating the need for further studies to investigate the relationship between solriamfetol and these new AEs.
Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management.
Sleep Med X
December 2024
Division of Adult Psychiatry, Department of Psychiatry, University Hospitals of Geneva, 2 Chemin du Petit-Bel-Air, CH-1226, Thonex, Switzerland.
Article Synopsis
- Narcolepsy and obstructive sleep apnea (OSA) are major causes of excessive daytime sleepiness (EDS), but differentiating between them can be challenging, especially when they occur in the same patient due to limited management guidelines.
- A literature review identified that between 24.8% and 51.4% of adults with narcolepsy type 1 (NT1) also have OSA, yet there is a lack of comprehensive studies on treating EDS in these patients.
- The link between NT1 and OSA may be due to orexin's role in regulating sleep and breathing, and more research is needed to explore effective treatments and understand orexin's function in sleep disorders related to EDS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!